Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years Su-Hyun Kim, MD; Woojun Kim, MD, PhD; Xue Feng Li, MD, MSc; In-Ja Jung, RN; Ho Jin Kim, MD, PhD Arch Neurol. ?2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154 Objective? To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO).
Case Reports in Medicine Volume 2011 (2011), Article ID 393568, 4 pages doi:10.1155/2011/393568 Case Report Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature M.
Physical therapy is an exercise treatment methodology aimed at the treatment and curing of certain physical ailments, through exercise and stretching. While at the same time preventing the chances of any re-occurrences further on down the road.
Keywords: albumin; antioxidant; bilirubin; neuromyelitis optica; uric acid Background: Oxidative stress plays a central role in neuropathology of multiple sclerosis (MS). The patients with MS have low antioxidant status. Antioxidant therapy may represent an attractive treatment of MS
Abstract Aquaporin-4 (AQP4) is a water-selective transporter expressed in astrocytes throughout the central nervous system, as well as in kidney, lung, stomach and skeletal muscle.
Voiding dysfunction, either urinary incontinence or retention, can have a debilitating effect upon the individual’s daily quality of life. Patients with these conditions often face many challenges in their everyday lives and can become preoccupied with constant trips to the bathroom, fear of leaking episodes and sleepless nights.
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Pellkofer HL , Krumbholz M , Berthele A , Hemmer B , Gerdes LA , Havla J , Bittner R , Canis M , Meinl E , Hohlfeld R , Kuempfel T
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that predominantly affects the optic nerves and spinal cord. Recombinant antibodies (rAbs) generated from clonally expanded plasma cells in an NMO patient are specific to AQP4 and pathogenic. We screened phage-displayed peptide libraries with these rAbs, and identified 14 high affinity linear and conformational peptides
OBJECTIVE: To investigate the clinical relevance of memory Th17 cells in patients with neuromyelitis optica (NMO) or multiple sclerosis (MS). PATIENTS AND METHODS: The proportion of peripheral memory Th17 cells was determined by flow cytometry. Sera IL-17A and IL-23 levels were detected by ELISA kits
Neuromyelitis optica (NMO, Devic’s disease), an uncommon demyelinating neuro-immunological disease, can be associated with autoimmune diseases. In SLE associated forms anti-aquaporin-4 antibody positivity can help differentiating between SLE nerve system manifestation and NMO.
Interferon-b (IFN-b) is the major treatment for multiple sclerosis. However, this treatment is not always effective. Here we have found congruence in outcome between responses to IFN-b in experimental autoimmune encephalomyelitis (EAE) and relapsing-remitting multiple sclerosis (RRMS).
OBJECTIVE: To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO). DESIGN: Prospective open-label study.